Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Acinetobacter baumannii and Staphylococcus aureus
Journal of Antimicrobial Chemotherapy · 03.09.2024 · 79 (9) · 2246-2250
DOI: 10.1093/jac/dkae220 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 16.07.2024. Verfasst von Ran Jing und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Microbial Sensitivity Tests, Tetracyclines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National High Level Hospital.
Abstract (Originalsprache)
Objectives
To establish the epidemiology cut-off (ECOFF) values of eravacycline against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus, from a multi-centre study in China.
Methods
We collected 2500 clinical isolates from five hospitals in China from 2017 to 2020. The MICs of eravacycline were determined using broth microdilution. The ECOFF values of eravacycline against the five species commonly causing cIAIs were calculated using visual estimation and ECOFFinder following the EUCAST guideline.
Results
The MICs of eravacycline against all the strains were in the range of 0.004–16 mg/L. The ECOFF values of eravacycline were 0.5 mg/L for E. coli, 2 mg/L for K. pneumonia and E. cloacae, and 0.25 mg/L for A. baumannii and S. aureus, consistent with the newest EUCAST publication of eravacycline ECOFF values for the populations. No discrepancy was found between the visually estimated and 99.00% ECOFF values calculated using ECOFFinder.
Conclusions
The determined ECOFF values of eravacycline against the five species can assist in distinguishing wild-type from non-wild-type strains. Given its promising activity, eravacycline may represent a member of the tetracycline class in treating cIAIs caused by commonly encountered Gram-negative and Gram-positive pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Beijing, China.
- Department of Clinical Infectious Diseases, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.
- Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
- Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, China.
- Institute of Antibiotics, Huashan Hospital, Fudan University, and Key Laboratory of Clinical Pharmacology of Antibiotics, Shanghai, China.
ORCID-Profile: Qi-Wen Yang
Förderung
- National High Level Hospital
Zitieren
APA
Jing, R., Yi, Q. L., Zhuo, C., Kang, W., Yang, Q. W., Yu, Y. S., Zheng, B., Li, Y., Hu, F. P., Yang, Y., Lin, J., Zhang, G., Zhang, J. J., Wang, T., Li, J., Zhuo, C. Y., Li, X., Zhu, Y. F., & Xu, Y. C. (2024). Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Acinetobacter baumannii and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 79(9), 2246-2250. https://doi.org/10.1093/jac/dkae220
Vancouver
Jing R, Yi QL, Zhuo C, Kang W, Yang QW, Yu YS, et al. Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Acinetobacter baumannii and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 2024;79(9):2246-2250. doi:10.1093/jac/dkae220
BibTeX
@article{Jing2024,
author = {Jing, Ran and Yi, Qiao-Lian and Zhuo, Chao and Kang, Wei and Yang, Qi-Wen and Yu, Yun-Song and Zheng, Bo and Li, Yun and Hu, Fu-Pin and Yang, Yang and Lin, Jie and Zhang, Ge and Zhang, Jing-Jia and Wang, Tong and Li, Jin and Zhuo, Chu-Yue and Li, Xue and Zhu, Yun-Fan and Xu, Ying-Chun},
title = {Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Acinetobacter baumannii and Staphylococcus aureus},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {9},
pages = {2246--2250},
doi = {10.1093/jac/dkae220}
}
EUVIMED